Wholomics develops highly accurate, cost-effective liquid biopsy tests for early cancer detection. These advanced diagnostic tools enable healthcare professionals to quickly identify high-risk individuals using a simple blood draw. The company focuses on providing minimally-invasive screening solutions to support proactive healthcare and precision medicine strategies.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer screening methods often detect the disease at later stages, leading to reduced treatment options and lower survival rates. Traditional screening methods can be invasive, costly, and may not be suitable for frequent testing, hindering early detection efforts.
Solution
Wholomics offers a multi-cancer early detection (MCED) test that analyzes blood samples to identify cancer-specific biomarkers, enabling the detection of multiple cancer types at early stages. The liquid biopsy technology allows for a minimally invasive approach to cancer screening, improving patient compliance and enabling frequent monitoring. By detecting cancer early, Wholomics aims to improve treatment outcomes and increase survival rates through timely intervention. The test provides healthcare professionals with a precise and cost-effective tool for proactive cancer screening and personalized treatment strategies.
Target Audience
The primary audience includes adults at average or high risk of developing cancer, healthcare professionals seeking advanced diagnostic tools, and organizations focused on proactive healthcare solutions.
Features
- Utilizes liquid biopsy technology for minimally invasive cancer detection.
- Identifies cancer-specific biomarkers in blood samples.
- Detects multiple cancer types in early stages.
- Provides precise and cost-effective screening.